Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price
Acutaas Chemicals flagged a risk in a quarterly results development for Q2FY27.
· LiveMint Markets
Pharma results may benefit from rupee depreciation, particularly for exporters, though elevated freight and input costs remain risks. InCred sees potential pressure at Dr Reddy’s, Divi’s, Lupin, Cipla, Torrent Pharma and Blue Jet Healthcare in Q2FY27. Check its top stock picks in the segment.
Key facts
- Period
- Q2FY27
The analysis
Against that, the stock is -3.7% on the day at ₹3,056.40, and has returned -11.6% over three months. It sits 17% below its 52-week high. The pharma & healthcare sector has moved +0.1% over the same period, so Acutaas Chemicals is running 11.7 points behind its peers.
With Acutaas Chemicals, Mankind Pharma and Dr Reddy all implicated, this reads as a Pharma & Healthcare-level move rather than a company-specific one, which is the more durable kind of signal.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- It touches several names at once (ACUTAAS, MANKIND, DRREDDY, CIPLA), which points to a sector-level rather than company-specific driver.
- Sector exposure: Pharma & Healthcare, Chemicals.
In this story
Related coverage
Q2 results today: TCS, Indian Bank, 4 others set to announce earnings
TCS shares rise ahead of Q2 results; Mphasis, Coforge, Infosys also gain; here's why
Jefferies cuts target prices for BSE, Turtlemint & other stocks ahead of Q2 results. Check list
TCS, Infosys, HCL Tech, other IT stocks jump up to 3% despite weak market sentiment. What to expect as Q2 earnings season begins?
Fino Payments Bank share price rallies 17% after Q2 business update